<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with OASIS Tables with MathML3 v1.2 20190208//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-archive-oasis-article1-mathml3.dtd?><?SourceDTD.Version 1.2?><?ConverterInfo.XSLTName jpoasis-nisons2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Enzyme Inhib Med Chem</journal-id><journal-id journal-id-type="iso-abbrev">J Enzyme Inhib Med Chem</journal-id><journal-title-group><journal-title>Journal of Enzyme Inhibition and Medicinal Chemistry</journal-title></journal-title-group><issn pub-type="ppub">1475-6366</issn><issn pub-type="epub">1475-6374</issn><publisher><publisher-name>Taylor &#x00026; Francis</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7738283</article-id><article-id pub-id-type="pmid">33307878</article-id><article-id pub-id-type="doi">10.1080/14756366.2020.1852556</article-id><article-id pub-id-type="publisher-id">1852556</article-id><article-version vocab="JAV" vocab-identifier="http://www.niso.org/publications/rp/RP-8-2008.pdf" vocab-term="Version of Record" article-version-type="VoR">Version of Record</article-version><article-categories><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Research Paper</subject></subj-group></article-categories><title-group><article-title>Discovery of orally active chalcones as histone lysine specific demethylase 1 inhibitors for the treatment of leukaemia</article-title><alt-title alt-title-type="left-running-head">Y. Li et al.</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Li</surname><given-names>Yang</given-names></name><xref ref-type="aff" rid="AF0001">a</xref></contrib><contrib contrib-type="author"><name><surname>Sun</surname><given-names>Ying</given-names></name><xref ref-type="aff" rid="AF0001">a</xref></contrib><contrib contrib-type="author"><name><surname>Zhou</surname><given-names>Yang</given-names></name><xref ref-type="aff" rid="AF0002">b</xref></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Xinyang</given-names></name><xref ref-type="aff" rid="AF0001">a</xref></contrib><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Huan</given-names></name><xref ref-type="aff" rid="AF0001">a</xref></contrib><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Guojun</given-names></name><xref ref-type="aff" rid="AF0001">a</xref><xref ref-type="corresp" rid="AN0001"/></contrib><aff id="AF0001"><label>a</label><institution>Department of Hematology, Shengjing Hospital of China Medical University</institution>, <city>Shenyang</city>, <country>China</country>;</aff><aff id="AF0002"><label>b</label><institution>Department of Oncology, Shengjing Hospital of China Medical University</institution>, <city>Shenyang</city>, <country>China</country></aff></contrib-group><author-notes><fn id="AUFN1"><p>Supplemental data for this article can be accessed <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1080/14756366.2020.1852556"><underline>here</underline></ext-link>.</p></fn><corresp id="AN0001">CONTACT Guojun Zhang <email>zhangguojun1977_sj@163.com</email><institution>Department of Hematology, Shengjing Hospital of China Medical University</institution>, <city>Shenyang</city>, <postal-code>110000</postal-code>, <country>China</country></corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>13</day><month>12</month><year>2020</year></pub-date><pub-date date-type="collection" publication-format="electronic"><year>2021</year></pub-date><volume>36</volume><issue>1</issue><fpage seq="21">207</fpage><lpage>217</lpage><permissions><copyright-statement>&#x000a9; 2020 The Author(s). Published by Informa UK Limited, trading as Taylor &#x00026; Francis Group.</copyright-statement><copyright-year>2020</copyright-year><copyright-holder>The Author(s)</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="IENZ_36_1852556.pdf"/><abstract><title>Abstract</title><p>Histone lysine specific demethylase 1 (LSD1) has emerged as an attractive molecule target for the discovery of potently anticancer drugs to treat leukaemia. In this study, a series of novel chalcone derivatives were designed, synthesised and evaluated for their inhibitory activities against LSD1 <italic>in&#x000a0;vitro</italic>. Among all these compounds, <bold>D6</bold> displayed the best LSD1 inhibitory activity with an IC<sub>50</sub> value of 0.14&#x02009;&#x003bc;M. In the cellular level, compound <bold>D6</bold> can induce the accumulation of H3K9me1/2 and inhibit cell proliferation by inactivating LSD1. It exhibited the potent antiproliferative activity with IC<sub>50</sub> values of 1.10&#x02009;&#x003bc;M, 3.64&#x02009;&#x003bc;M, 3.85&#x02009;&#x003bc;M, 1.87&#x02009;&#x003bc;M, 0.87&#x02009;&#x003bc;M and 2.73&#x02009;&#x003bc;M against HAL-01, KE-37, P30-OHK, SUP-B15, MOLT-4 and LC4-1 cells, respectively. Importantly, compound <bold>D6</bold> significantly suppressed MOLT-4 xenograft tumour growth <italic>in&#x000a0;vivo</italic>, indicating its great potential as an orally bioavailable candidate for leukaemia therapy.</p></abstract><abstract abstract-type="graphical"><title>Graphical Abstract</title><fig id="UF0001" orientation="portrait" position="anchor"><graphic content-type="color" xlink:href="IENZ_A_1852556_UF0001_C"/></fig></abstract><kwd-group kwd-group-type="author"><title>Keywords</title><kwd>Histone lysine specific demethylase 1</kwd><kwd>chalcone</kwd><kwd>H3K9me1/2</kwd><kwd>leukaemia</kwd><kwd>MOLT-4 xenograft</kwd></kwd-group><counts><fig-count count="10"/><table-count count="1"/><page-count count="11"/><word-count count="5585"/></counts></article-meta></front><body><sec sec-type="intro" id="S0001" disp-level="1"><title>Introduction</title><p>Histone lysine specific demethylase 1 (LSD1) has been an epigenetic target for cancer therapy since its identification in 2004<xref rid="CIT0001" ref-type="bibr"><sup>1</sup></xref>. Aberrant over-expression of LSD1 is observed in various leukaemia cell lines and is closely associated with proliferation, migration and invasion<xref rid="CIT0002" ref-type="bibr"><sup>2&#x02013;4</sup></xref>. These findings underscore the biological importance of LSD1 and therapeutic potential of LSD1 inhibitors for leukaemia therapy<xref rid="CIT0005" ref-type="bibr"><sup>5</sup></xref>. LSD1 inhibitors (<bold>Iadademstat</bold>, <bold>GSK2879552</bold> and <bold>CC-90011</bold>) have entered the clinical stages and are used to treat leukaemia (<xref ref-type="fig" rid="F0001">Figure 1</xref>)<xref rid="CIT0006" ref-type="bibr"><sup>6</sup></xref>. <bold>Dithiocarbamate 26</bold> and <bold>(Bis)urea 31</bold> as potent LSD1 inhibitors also effectively reduce the tumour growth against different human cancer cells<xref rid="CIT0007" ref-type="bibr"><sup>7</sup></xref><sup>,</sup><xref rid="CIT0008" ref-type="bibr"><sup>8</sup></xref>.</p><fig id="F0001" orientation="portrait" position="float"><label>Figure 1.</label><caption><p>Chemical structures of LSD1 inhibitors.</p></caption><graphic content-type="black-white" xlink:href="IENZ_A_1852556_F0001_B"/></fig><p>Chalcones as 1,3-diaryl-2-propene-1-ones with the enone system between two aromatic rings possess a wide range of biological activities such as antibacterial, antioxidative, anticancer, antileishmanial, antiulcer, antiangiogenic, antiviral, immunosuppressive and anti-inflammatory activities<xref rid="CIT0009" ref-type="bibr"><sup>9&#x02013;11</sup></xref>. More particularly, a number of synthetic and natural chalcones exhibited the potent anticancer activity against many cancer cell lines<xref rid="CIT0012" ref-type="bibr"><sup>12</sup></xref><sup>,</sup><xref rid="CIT0013" ref-type="bibr"><sup>13</sup></xref>. Chalcone <bold>1</bold> (<xref ref-type="fig" rid="F0002">Figure 2</xref>), a natural product isolated from the root of <italic>Glycyrrhiza inflata</italic>, could inhibit the drug transport function of ABCG2 and reverse ABCG2-mediated multidrug resistance in human multidrug-resistant cancer cell lines<xref rid="CIT0014" ref-type="bibr"><sup>14</sup></xref>. Chalcone <bold>2</bold> exhibited the reduction of tumour cell growth combined with inhibition of Notch1 intracellular domain<xref rid="CIT0015" ref-type="bibr"><sup>15</sup></xref>. Naphthalene-chalcone derivative <bold>3</bold> was found to induce significant cell cycle arrest at the G2/M phase and cell apoptosis against MCF-7 cell line<xref rid="CIT0016" ref-type="bibr"><sup>16</sup></xref>. Chalcone <bold>4</bold> displayed the potent antiproliferative activity against cancer cells by up-regulating the expression of P53 protein<xref rid="CIT0017" ref-type="bibr"><sup>17</sup></xref>.</p><fig id="F0002" orientation="portrait" position="float"><label>Figure 2.</label><caption><p>Chemical structures of anticancer chalcone derivatives.</p></caption><graphic content-type="black-white" xlink:href="IENZ_A_1852556_F0002_B"/></fig><p>Molecular hybridisation is a new concept in drug design and development based on the combination of bioactive moieties of different compounds to produce a new hybrid with the improved affinity and efficacy<xref rid="CIT0018" ref-type="bibr"><sup>18</sup></xref>. These above interesting findings about LSD1 inhibitors and our continuous quest to identify more potently anticancer agents led to the molecular hybridisation of a LSD1 scaffold and an antitumor fragment to generate a new LSD1 inhibitor with the potentially anticancer activity. As shown in <xref ref-type="fig" rid="F0003">Figure 3</xref>, a molecular hybridisation strategy based on the structures of the reported LSD1 inhibitor <bold>26</bold> and antitumor agent <bold>4</bold> produced a scaffold that has three parts: (i) chalcone as an anticancer pharmacophore; (ii) a dithiocarbamate unit as the potential LSD1 moiety; (iii) an amide linker between chalcone and dithiocarbamate to form the hydrogen bond with LSD1. To the best of our knowledge, there have been few literature reports regarding anticancer chalcone derivatives as potent LSD1 inhibitors so far.</p><fig id="F0003" orientation="portrait" position="float"><label>Figure 3.</label><caption><p>Rational design of chalcone based LSD1 inhibitors.</p></caption><graphic content-type="color" xlink:href="IENZ_A_1852556_F0003_C"/></fig></sec><sec sec-type="materials" id="S0002" disp-level="1"><title>Materials and methods</title><sec id="S0002-S2001" disp-level="2"><title>General</title><p>Reagents and solvents were purchased (Innochem, Beijing, China). Melting points were determined on a micromelting apparatus (Tianjin XinZhou Science and Technology Co., Ltd, Tianjin, China). <sup>1</sup>H NMR and <sup>13&#x02009;</sup>C NMR spectra were recorded on a NMR spectrometer (DNP-NMR spectrometer, HuZhou Jingke Instrument Co., Ltd, FuZhou, China). High resolution mass spectra of all derivatives were recorded on a Waters Micromass Q-T of Micromass spectrometer by electrospray ionisation (Skyray Instrument, JiangShu, China).</p></sec><sec id="S0002-S2002" disp-level="2"><title>General procedure for the synthesis of compounds C1&#x0223c;C4</title><p>Chalcone derivatives <bold>B</bold> were prepared by a condensation reaction from 1&#x02013;(4-azidophenyl)ethan-1-one <bold>A</bold> and different benzaldehydes without purification. To a solution of triphenylphosphine (1&#x02009;mmol), chalcone intermediates <bold>B</bold> (2&#x02009;mmol), and tetrahydrofuran (12&#x02009;ml) was added water (3&#x02009;ml), the mixture was stirred for 4&#x02009;h. Upon the completion, ethyl acetate and water were added. The organic layers were washed with water for several times to remove the tetrahydrofuran, and then evaporated to give the crude products. The crude product (1&#x02009;mmol), chloroacetyl chloride (1.2&#x02009;mmol), and triethylamine (0.5&#x02009;mmol) were dissolved in acetone (10&#x02009;ml) to stir for 8&#x02009;h at room temperature. Upon completion, the system was purified with column chromatography (hexane: ethyl acetate = 9:1) to obtain analogues <bold>C1&#x0223c;C4</bold>. Compound C4 was a reported chalcone intermediate from the previous reference [<xref rid="CIT0019" ref-type="bibr">19</xref>].</p><sec id="S0002-S2002-S3001" disp-level="3"><title>(E)-2-Chloro-N-(4-cinnamoylphenyl)acetamide (C1)</title><p>Yellow solid, yield: 65%; m.p.: 145&#x02013;147&#x02009;&#x000b0;C. <sup>1</sup>H NMR (400&#x02009;MHz, CDCl<sub>3</sub>) &#x003b4; 8.45 (s, 1H), 8.06 (d, <italic>J</italic>&#x02009;=&#x02009;7.7&#x02009;<italic>Hz</italic>, 2H), 7.82 (d, <italic>J</italic>&#x02009;=&#x02009;15.8&#x02009;<italic>Hz</italic>, 1H), 7.73 (d, <italic>J</italic>&#x02009;=&#x02009;8.0&#x02009;<italic>Hz</italic>, 2H), 7.65 (m, 2H), 7.53 (d, <italic>J</italic>&#x02009;=&#x02009;15.8&#x02009;<italic>Hz</italic>, 1H), 7.42 (m, 3H), 4.23 (s, 2H). <sup>13&#x02009;</sup>C NMR (100&#x02009;MHz, CDCl<sub>3</sub>) &#x003b4; 188.96, 164.05, 144.87, 140.74, 134.87, 134.74, 130.62, 129.98, 129.00, 128.49, 121.68, 119.41, 42.90. HRMS (ESI) calcd. for C<sub>17</sub>H<sub>15</sub>ClNO<sub>2</sub> [M&#x02009;+&#x02009;H]<sup>+</sup>: 300.0791, found: 300.0795.</p></sec><sec id="S0002-S2002-S3002" disp-level="3"><title>(E)-2-Chloro-N-(4&#x02013;(3-(3-fluorophenyl)acryloyl)phenyl)acetamide (C2)</title><p>Yellow solid, yield: 90%; m.p.: 156&#x02013;158&#x02009;&#x000b0;C. <sup>1</sup>H NMR (400&#x02009;MHz, CDCl<sub>3</sub>) &#x003b4; 8.46 (s, 1H), 8.06 (d, <italic>J</italic>&#x02009;=&#x02009;8.3&#x02009;<italic>Hz</italic>, 2H), 7.83&#x02009;&#x02212;&#x02009;7.67 (m, 3H), 7.54 (d, <italic>J</italic>&#x02009;=&#x02009;15.8&#x02009;<italic>Hz</italic>, 1H), 7.46&#x02009;&#x02212;&#x02009;7.30 (m, 3H), 7.16&#x02009;&#x02212;&#x02009;7.06 (m, 1H), 4.23 (s, 2H). <sup>13&#x02009;</sup>C NMR (100&#x02009;MHz, CDCl<sub>3</sub>) &#x003b4; 188.54, 164.05, 143.30, 143.27, 140.90, 137.16, 134.44, 130.48, 130.00, 124.57, 122.81, 119.43, 117.30, 114.38, 42.89. HRMS (ESI) calcd. for C<sub>17</sub>H<sub>13</sub>ClFNO<sub>2</sub> [M&#x02009;+&#x02009;H]<sup>+</sup>: 317.0619, found: 317.0623.</p></sec><sec id="S0002-S2002-S3003" disp-level="3"><title>(E)-2-Chloro-N-(4&#x02013;(3-(2-fluorophenyl)acryloyl)phenyl)acetamide (C3)</title><p>Yellow solid, yield: 86%; m.p.: 167&#x02013;169&#x02009;&#x000b0;C.<sup>1</sup>H NMR (400&#x02009;MHz, DMSO-d<sub>6</sub>) &#x003b4; 10.70 (s, 1H), 8.23&#x02009;&#x02212;&#x02009;8.09 (m, 3H), 7.99 (d, <italic>J</italic>&#x02009;=&#x02009;15.8&#x02009;<italic>Hz</italic>, 1H), 7.89&#x02009;&#x02212;&#x02009;7.77 (m, 3H), 7.57&#x02009;&#x02212;&#x02009;7.49 (m, 1H), 7.33 (m, 2H), 4.34 (s, 2H). <sup>13&#x02009;</sup>C NMR (100&#x02009;MHz, DMSO-d<sub>6</sub>) &#x003b4; 187.35, 165.21, 142.99, 134.64, 134.59, 132.51, 129.99, 129.06, 124.92, 124.89, 124.05, 124.00, 118.77, 115.93, 43.59. HRMS (ESI) calcd. for C<sub>17</sub>H<sub>14</sub>ClFNO<sub>2</sub> [M&#x02009;+&#x02009;H]<sup>+</sup>: 318.0697, found: 318.0699.</p></sec></sec><sec id="S0002-S2003" disp-level="2"><title>General procedure for the synthesis of compounds D1&#x0223c;D7</title><p>To a solution of analogues <bold>C1&#x0223c;C4</bold> (2&#x02009;mmol) in acetone (20&#x02009;ml) was added carbon disulphide (3&#x02009;mmol), sodium phosphate dodecahydrate (1.5&#x02009;mmol) and piperazine derivatives (2&#x02009;mmol). The reaction mixture was stirred for 12&#x02009;h. After the end of the reaction was established by TLC, the solvent was removed under vacuum, and excess saturated Na<sub>2</sub>CO<sub>3</sub> solution was added. The resulted mixture was extracted with ethyl acetate, dried over MgSO<sub>4</sub>, filtered, and concentrated under vacuum. The product was purified by a silica gel column using ethyl acetate and petroleum ether as eluent to afford compounds <bold>D1&#x0223c;D7</bold>. All the <sup>1</sup>H NMR and <sup>13&#x02009;</sup>C NMR spectra of compounds <bold>D1&#x0223c;D7</bold> were listed in <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1080/14756366.2020.1852556">Supporting Information</ext-link>.</p><sec id="S0002-S2003-S3001" disp-level="3"><title>(E)-2-((4&#x02013;(3-(4-Fluorophenyl)acryloyl)phenyl)amino)-2-oxoethyl-4-ethylpiperazine-1-carbodithioate (D1)</title><p>Yellow solid, yield: 72%; m.p.: 182&#x02013;184&#x02009;&#x000b0;C.<sup>1</sup>H NMR (400&#x02009;MHz, CDCl<sub>3</sub>) &#x003b4; 9.40 (s, 1H), 7.93 (d, <italic>J</italic>&#x02009;=&#x02009;8.7&#x02009;<italic>Hz</italic>, 2H), 7.69 (d, <italic>J</italic>&#x02009;=&#x02009;15.7&#x02009;<italic>Hz</italic>, 1H), 7.61&#x02009;&#x02212;&#x02009;7.52 (m, 4H), 7.37 (d, <italic>J</italic>&#x02009;=&#x02009;15.7&#x02009;<italic>Hz</italic>, 1H), 7.04 (m, 2H), 4.33 (s, 2H), 4.20 (s, 2H), 3.92 (s, 2H), 2.50 (s, 4H), 2.40 (q, <italic>J</italic>&#x02009;=&#x02009;7.2&#x02009;<italic>Hz</italic>, 2H), 1.04 (t, <italic>J</italic>&#x02009;=&#x02009;7.2&#x02009;<italic>Hz</italic>, 3H). <sup>13</sup>C NMR (100&#x02009;MHz, CDCl<sub>3</sub>) &#x003b4; 195.44, 188.67, 167.31, 143.09, 142.27, 133.67, 130.34, 130.25, 129.84, 121.57, 121.55, 119.17, 116.20, 115.98, 52.04, 51.78, 40.33, 11.94. HRMS (ESI) calcd. for C<sub>24</sub>H<sub>27</sub>FN<sub>3</sub>O<sub>2</sub>S<sub>2</sub> [M&#x02009;+&#x02009;H]<sup>+</sup>: 472.1529, found: 472.1536.</p></sec><sec id="S0002-S2003-S3002" disp-level="3"><title>(E)-2-((4-Cinnamoylphenyl)amino)-2-oxoethyl-4-methylpiperazine-1-carbodithioate (D2)</title><p>Yellow solid, yield: 92%; m.p.: 175&#x02013;177&#x02009;&#x000b0;C. <sup>1</sup>H NMR (400&#x02009;MHz, CDCl<sub>3</sub>) &#x003b4; 9.47 (s, 1H), 8.01 (d, <italic>J</italic>&#x02009;=&#x02009;8.7&#x02009;<italic>Hz</italic>, 2H), 7.80 (d, <italic>J</italic>&#x02009;=&#x02009;15.7&#x02009;<italic>Hz</italic>, 1H), 7.69&#x02009;&#x02212;&#x02009;7.63 (m, 4H), 7.53 (d, <italic>J</italic>&#x02009;=&#x02009;15.7&#x02009;<italic>Hz</italic>, 1H), 7.42 (m, 3H), 4.40 (s, 2H), 4.27 (s, 2H), 3.98 (s, 2H), 2.57&#x02009;&#x02212;&#x02009;2.50 (m, 4H), 2.34 (s, 3H). <sup>13&#x02009;</sup>C NMR (100&#x02009;MHz, CDCl<sub>3</sub>) &#x003b4; 195.65, 188.91, 167.28, 144.44, 142.21, 134.97, 133.76, 130.45, 129.87, 128.94, 128.42, 121.84, 119.15, 54.29, 45.54, 40.35. HRMS (ESI) calcd. for C<sub>23</sub>H<sub>26</sub>N<sub>3</sub>O<sub>2</sub>S<sub>2</sub> [M&#x02009;+&#x02009;H]<sup>+</sup>: 440.1466, found: 440.1469.</p></sec><sec id="S0002-S2003-S3003" disp-level="3"><title>(E)-2-((4-Cinnamoylphenyl)amino)-2-oxoethyl -4-ethylpiperazine-1-carbodithioate (D3)</title><p>Yellow solid, yield: 82%; m.p.: 181&#x02013;183&#x02009;&#x000b0;C. <sup>1</sup>H NMR (400&#x02009;MHz, CDCl<sub>3</sub>) &#x003b4; 9.46 (s, 1H), 8.01 (d, <italic>J</italic>&#x02009;=&#x02009;8.7&#x02009;<italic>Hz</italic>, 2H), 7.80 (d, <italic>J</italic>&#x02009;=&#x02009;15.7&#x02009;<italic>Hz</italic>, 1H), 7.69&#x02009;&#x02212;&#x02009;7.61 (m, 4H), 7.52 (d, <italic>J</italic>&#x02009;=&#x02009;15.7&#x02009;<italic>Hz</italic>, 1H), 7.42 (m, 3H), 4.40 (s, 2H), 4.27 (s, 2H), 3.99 (s, 2H), 2.57 (m, 4H), 2.47 (q, <italic>J</italic>&#x02009;=&#x02009;7.2&#x02009;<italic>Hz</italic>, 2H), 1.11 (t, <italic>J</italic>&#x02009;=&#x02009;7.2&#x02009;<italic>Hz</italic>, 3H). <sup>13&#x02009;</sup>C NMR (100&#x02009;MHz, CDCl<sub>3</sub>) &#x003b4; 195.44, 188.92, 167.31, 144.44, 142.21, 134.98, 133.76, 130.44, 129.86, 128.94, 128.41, 121.85, 119.15, 52.04, 51.79, 40.32, 11.95. HRMS (ESI) calcd. for C<sub>24</sub>H<sub>28</sub>N<sub>3</sub>O<sub>2</sub>S<sub>2</sub> [M&#x02009;+&#x02009;H]<sup>+</sup>: 454.1623, found: 454.1627.</p></sec><sec id="S0002-S2003-S3004" disp-level="3"><title>(E)-2-((4&#x02013;(3-(3-Fluorophenyl)acryloyl)phenyl)amino)-2-oxoethyl-4-methylpiperazine-1-carbodithioate (D4)</title><p>Yellow solid, yield: 85%; m.p.: 135&#x02013;137&#x02009;&#x000b0;C. <sup>1</sup>H NMR (400&#x02009;MHz, CDCl<sub>3</sub>) &#x003b4; 9.40 (s, 1H), 7.95 (d, <italic>J</italic>&#x02009;=&#x02009;15.7&#x02009;<italic>Hz</italic>, 1H), 7.84 (d, <italic>J</italic>&#x02009;=&#x02009;8.5&#x02009;<italic>Hz</italic>, 2H), 7.57 (m, 4H), 7.32 (s, 1H), 7.10 (m, 2H), 4.32 (s, 2H), 4.19 (s, 2H), 3.91 (s, 2H), 2.47 (s, 4H), 2.27 (s, 3H). <sup>13&#x02009;</sup>C NMR (100&#x02009;MHz, CDCl<sub>3</sub>) &#x003b4; 195.88, 194.63, 187.85, 166.26, 141.32, 136.10, 132.55, 131.84, 130.75, 128.93, 128.62, 123.45, 118.14, 118.00, 115.37, 53.25, 44.49, 39.32, 25.41. HRMS (ESI) calcd. for C<sub>23</sub>H<sub>25</sub>FN<sub>3</sub>O<sub>2</sub>S<sub>2</sub> [M&#x02009;+&#x02009;H]<sup>+</sup>: 458.1372, found: 458.1378.</p></sec><sec id="S0002-S2003-S3005" disp-level="3"><title>(E)-2-((4&#x02013;(3-(3-Fluorophenyl)acryloyl)phenyl)amino)-2-oxoethyl-4-ethylpiperazine-1-carbodithioate (D5)</title><p>Yellow solid, yield: 90%; m.p.: 136&#x02013;138&#x02009;&#x000b0;C. <sup>1</sup>H NMR (400&#x02009;MHz, CDCl<sub>3</sub>) &#x003b4; 9.40 (s, 1H), 7.95 (d, <italic>J</italic>&#x02009;=&#x02009;15.7&#x02009;<italic>Hz</italic>, 1H), 7.84 (d, <italic>J</italic>&#x02009;=&#x02009;8.5&#x02009;<italic>Hz</italic>, 2H), 7.57 (m, 5H), 7.32 (s, 1H), 7.10 (m, 1H), 4.32 (s, 2H), 4.19 (s, 2H), 3.91 (s, 2H), 2.51 (s, 4H), 2.45 (q, <italic>J</italic>&#x02009;=&#x02009;7.2&#x02009;<italic>Hz</italic>, 2H), 2.27 (t, <italic>J</italic>&#x02009;=&#x02009;7.2&#x02009;<italic>Hz</italic>, 3H). <sup>13&#x02009;</sup>C NMR (100&#x02009;MHz, CDCl<sub>3</sub>) &#x003b4; 195.87, 194.43, 187.85, 166.29, 159.43, 141.33, 136.08, 132.55, 131.84, 130.75, 128.93, 123.45, 122.03, 118.00, 115.37, 51.00, 50.77, 39.30, 25.41, 10.89. HRMS (ESI) calcd. for C<sub>24</sub>H<sub>27</sub>FN<sub>3</sub>O<sub>2</sub>S<sub>2</sub> [M&#x02009;+&#x02009;H]<sup>+</sup>: 472.1529, found: 472.1535.</p></sec><sec id="S0002-S2003-S3006" disp-level="3"><title>Tert-butyl-(E)-4-(((2-((4&#x02013;(3-(2-fluorophenyl)acryloyl)phenyl)amino)-2-oxoethyl)thio)carbonothioyl)piperazine-1-carboxylate (D6)</title><p>Yellow solid, yield: 75%; m.p.: 160&#x02013;162&#x02009;&#x000b0;C. <sup>1</sup>H NMR (400&#x02009;MHz, CDCl<sub>3</sub>) &#x003b4; 9.31 (s, 1H), 7.94 (d, <italic>J</italic>&#x02009;=&#x02009;8.7&#x02009;<italic>Hz</italic>, 2H), 7.80 (d, <italic>J</italic>&#x02009;=&#x02009;15.7&#x02009;<italic>Hz</italic>, 1H), 7.61&#x02009;&#x02212;&#x02009;7.54 (m, 4H), 7.32 (m, 1H), 7.09 (m, 2H), 4.30 (s, 2H), 4.21 (s, 2H), 3.90 (s, 2H), 3.53 (s, 4H), 1.41 (s, 9H). <sup>13&#x02009;</sup>C NMR (100&#x02009;MHz, CDCl<sub>3</sub>) &#x003b4; 195.32, 187.87, 166.05, 161.96, 159.43, 153.29, 141.16, 136.18, 132.61, 130.69, 128.94, 123.49, 122.10, 118.15, 115.37, 115.15, 79.90, 51.14, 49.14, 39.29, 27.31. HRMS (ESI) calcd. for C<sub>27</sub>H<sub>31</sub>FN<sub>3</sub>O<sub>4</sub>S<sub>2</sub> [M&#x02009;+&#x02009;H]<sup>+</sup>: 544.1740, found: 544.1747.</p></sec><sec id="S0002-S2003-S3007" disp-level="3"><title>(E)-2-((4&#x02013;(3-(2-Fluorophenyl)acryloyl)phenyl)amino)-2-oxoethyl-4-benzylpiperazine-1-carbodithioate (D7)</title><p>Yellow solid, yield: 81%; m.p.: 130&#x02013;131&#x02009;&#x000b0;C. <sup>1</sup>H NMR (400&#x02009;MHz, CDCl<sub>3</sub>) &#x003b4; 9.40 (s, 1H), 7.94 (d, <italic>J</italic>&#x02009;=&#x02009;8.7&#x02009;<italic>Hz</italic>, 2H), 7.80 (d, <italic>J</italic>&#x02009;=&#x02009;15.7&#x02009;<italic>Hz</italic>, 1H), 7.61&#x02009;&#x02212;&#x02009;7.54 (m, 4H), 7.31 (m, 1H), 7.24 (m, 5H), 7.10 (m, 2H), 4.33 (s, 2H), 4.19 (s, 2H), 3.91 (s, 2H), 3.50 (s, 2H), 2.54 (s, 4H). <sup>13&#x02009;</sup>C NMR (100&#x02009;MHz, CDCl<sub>3</sub>) &#x003b4; 194.47, 187.85, 166.28, 161.95, 159.42, 141.27, 136.09, 132.53, 130.75, 128.92, 128.72, 128.18, 127.46, 126.62, 123.48, 123.33, 122.00, 118.13, 115.36, 61.24, 51.54, 49.47, 39.30. HRMS (ESI) calcd. for C<sub>29</sub>H<sub>29</sub>FN<sub>3</sub>O<sub>2</sub>S<sub>2</sub> [M&#x02009;+&#x02009;H]<sup>+</sup>: 534.1685, found: 534.1689.</p></sec></sec><sec id="S0002-S2004" disp-level="2"><title>Cell culture and cell viability assay</title><p>Cancer cell lines (Hela, 22RV1, Caco-2, BEL-7402, MOLT-4, OVCAR-3, HCT-8, HIC, IMR-32, HAL-01, KE-37, P30-OHK, SUP-B15 and LC4-1) were maintained in RPMI 1640 medium (Hyclone, Los Angeles, CA, USA) with 10% foetal bovine serum (Hyclone, Los Angeles, USA) and 1% penicillin-streptomycin (Hyclone, Los Angeles, USA) in a humidified atmosphere of 5% CO<sub>2</sub> and 95% air at 37&#x02009;&#x000b0;C. All cell lines were purchased from the China Centre for Type Culture Collection (CCTCC, China). Control containing sequence specific for LSD1 (GGCGAAGGTAGAGTACAGAGA) was described. The shRNA constructs were transfected into MOLT-4 cells using the Lonza Group nucleofector technology in accordance with the manufacturer&#x02019;s instructions<xref rid="CIT0020" ref-type="bibr"><sup>20</sup></xref>. MOLT-4&#x00026;shLSD1 cells and MOLT-4&#x00026;shControl cells were also established and cultured according to the published references [<xref rid="CIT0021" ref-type="bibr">21</xref>,<xref rid="CIT0022" ref-type="bibr">22</xref>]. After the incubation for 24&#x02009;h, cancer cell lines were cultured with the chalcone <bold>D6</bold> at different concentrations. Then, 20&#x02009;&#x003bc;L of MTT (3&#x02013;(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) solution (5&#x02009;mg/ml) was added and the cells were incubated for 4&#x02009;h. The absorbance was measured using a microplate reader (DeTie Technology Co., Ltd, NanJing, China).</p></sec><sec id="S0002-S2005" disp-level="2"><title>LSD1, MAO-A/B and CDK1/2 enzyme assay</title><p>The inhibition of LSD1 activity was evaluated according to reported references [<xref rid="CIT0023" ref-type="bibr">23</xref>,<xref rid="CIT0024" ref-type="bibr">24</xref>]. pET-28b-LSD1 (full length) was transfected into BL21 (DE). Then, the protein was induced with 0.25&#x02009;mmol/L IPTG following sonication and purified with Ni-NTA (Qiagen, Tubingen, Germany), Resource Q (GE, Pittsburgh, PA, USA) and Sephacryl S-200&#x02009;HR (GE, Pittsburgh, PA, USA). The fluorescence intensity was read using EnVision Plate Reader (PerkinElmer, Waltham, MA, USA) to calculate the inhibition rate. The MAO-A and MAO-B were purchased from Active Motif (Cat#31502, Cat#31503, Carlsbad, CA, USA). Biochemical Kits were purchased from Promega (MAO-Glo Assay, Madison, WI, USA). The inhibitory activities of MAO-A and MAO-B were obtained according to the reported reference [<xref rid="CIT0025" ref-type="bibr">25</xref>]. The inhibitory activities of CDK1 and CDK2 were obtained according to the reported reference [<xref rid="CIT0026" ref-type="bibr">26</xref>].</p></sec><sec id="S0002-S2006" disp-level="2"><title>Dialysis assay</title><p>In the dialysis experiment, after incubation of the recombinant LSD1 and chalcone derivatives for 1&#x02009;h at 37&#x02009;&#x000b0;C, we dialysed the reaction system against 50&#x02009;mmol/L HEPES buffer for 24&#x02009;h at 4&#x02009;&#x000b0;C and the reversibility was evaluated based on the activity of LSD1 in the dialysis tube.</p></sec><sec id="S0002-S2007" disp-level="2"><title>Dilution assay</title><p>LSD1 recombinant was incubated with the targeted compound, GSK-LSD1, or DMSO for 1&#x02009;h. Then, the reaction system was diluted for 80 times. Finally, the above stated method was applied to detect the activity of LSD1 before and after dilution.</p></sec><sec id="S0002-S2008" disp-level="2"><title>The ultrafiltration experiment</title><p>In the ultrafiltration experiment, LSD1 recombinant was incubated with a concentration of 20-fold IC 50 inhibitor. The mixture was then added to a 10&#x02009;kDa cut-off ultrafiltration tube (Millipore, Darmstadt, Germany) for centrifugation to remove the unbound compound. Finally, reversibility of the compound was evaluated by LSD1 assay for the upper chamber reaction system.</p></sec><sec id="S0002-S2009" disp-level="2"><title>Quantitative real-time PCR</title><p>Total RNA was isolated from MOLT-4&#x00026;shControl and MOLT-4&#x00026;shLSD1 cells with TRIzol reagent (Invitrogen, Carlsbad, CA, USA), the protocol was followed according to the manufacturer&#x02019;s instructions, and RNA was quantified with Nanodrop (Tianjin XinZhou Science and Technology Co., Ltd, Tianjin, China). Quantitative real-time PCR assays were carried out on the Applied Biosystems QuantStudio&#x02122; Real-Time PCR detected system (Thermos Fisher, Waltham, MA, USA) using the Q-PCR kit with SYBR green dye (Vazyme Biotech, Nanjing, China). The primer sequences were as follows: LSD1 forward primer sequence (5&#x02032;-3&#x02032;), GTGGACGAGTTGCCACATTTC; LSD1 reverse primer sequence (5&#x02032;-3&#x02032;), TGACCACAGCCATAGGATTCC; gapdh forward primer sequence (5&#x02032;-3&#x02032;), GCACCGTCAAGGCTGAGAAC; gapdh reverse primer sequence (5&#x02032;-3&#x02032;), TGGTGAAGACGCCAGTGGA.</p></sec><sec id="S0002-S2010" disp-level="2"><title>Western blotting</title><p>Western blot was performed with the total lysates using RIPA buffer (Hyclone, Los Angeles, CA, USA). Same amounts of protein were subjected to SDS-PAGE, and then transferred to nitrocellulose membranes (PALL, Cortland, NY, USA). After blocking with 5% milk solution, the membranes were incubated at 4&#x02009;&#x000b0;C with respective antibody overnight, followed by the incubation with a secondary antibody. Finally, the blot was visualised by enhanced chemiluminescence kit (Thermo Fisher, Waltham, MA, USA).</p></sec><sec id="S0002-S2011" disp-level="2"><title>Molecular docking studies</title><p>All molecular modelling studies were performed with the Autodock software (The Scripps Research Institute, San Diego, CA, USA). The crystal structure of LSD1 (PDB code: 5l3e) was downloaded from the RCSB protein database. The targeted compound was first generated using Pymol software. Following generation, the files were converted to the.pdbqt format using OpenBabel. It was then docked using AutoDockTools. The docked conformations and information were then docked and their resulting conformations were visualised using Pymol.</p></sec><sec id="S0002-S2012" disp-level="2"><title>Xenograft study</title><p>Animals were treated according to the protocols established by the ethics committee of Shengjing Hospital of China Medical University and the <italic>in&#x000a0;vivo</italic> experiments were carried out in accordance with the approved guidelines and approved by the ethics committee of Shengjing Hospital of China Medical University. BALB/c nude mice were purchased from Hunan Slack Scene of Laboratory Animal Co., Ltd. (Hunan, China). Xenograft models using human leukaemia cells, MOLT-4, were established in BALB/c mice. Then, mice were separated into vehicle group and treatment groups (60&#x02009;mg/kg and 100&#x02009;mg/kg). The treatment groups received compound <bold>D6</bold> by intragastric administration for a period of 21&#x02009;days.</p></sec></sec><sec sec-type="results" id="S0003" disp-level="1"><title>Results and discussion</title><sec id="S0003-S2001" disp-level="2"><title>Chemistry</title><p>A typical synthetic route for chalcone based LSD1 inhibitors is described in <xref ref-type="scheme" rid="s0001">Scheme 1</xref>. Chalcone B was prepared by the condensation reaction of 1&#x02013;(4-azidophenyl)ethan-1-one with different benzaldehydes. Intermediates <bold>C1</bold>&#x0223c;<bold>C4</bold> were formed by the reduction reaction and acylation reaction. Next, the intermediates <bold>C1</bold>&#x0223c;<bold>C4</bold> were reacted with carbon disulphide and piperazines under the presence of triethylamine to form chalcones <bold>D1</bold>&#x0223c;<bold>D7</bold>.</p><fig id="s0001" orientation="portrait" position="float"><label>Scheme 1.</label><caption><p>Synthesis of chalcones <bold>D1</bold>&#x0223c;<bold>D7</bold>. Reagents and Conditions: (a) different benzaldehydes, NaOH, EtOH; (b) Ph<sub>3</sub>P, THF/H<sub>2</sub>O = 4: 1; (c) chloroacetyl chloride, Et<sub>3</sub>N, acetone; (d) CS2, piperazine derivatives, Na<sub>3</sub>PO<sub>4</sub>.12H<sub>2</sub>O, acetone.</p></caption><graphic content-type="black-white" xlink:href="IENZ_A_1852556_SCH0001_B"/></fig></sec><sec id="S0003-S2002" disp-level="2"><title><italic>In vitro</italic> LSD1-inhibitory activity of chalcones C1&#x0223c;C4 and D1&#x0223c;D7</title><p>The LSD1 inhibitory activity of all synthesised compounds <bold>C1</bold>&#x0223c;<bold>C4</bold> and <bold>D1</bold>&#x0223c;<bold>D7</bold> was examined according to reported references [<xref rid="CIT0024" ref-type="bibr">24</xref>,<xref rid="CIT0027" ref-type="bibr">27</xref>]. Their results of inhibitory activities against LSD1 <italic>in&#x000a0;vitro</italic> were summarised in <xref rid="t0001" ref-type="table">Table 1</xref>. In this work, <bold>Dithiocarbamate 26</bold> and chalcone <bold>4</bold> were used as reference compounds. The replacement of the chlorine atom by the dithiocarbamate fragment resulted in a powerful improvement of LSD1 inhibitory activity for chalcone-dithiocarbamate derivatives <bold>D1</bold>&#x0223c;<bold>D7</bold> compared with the corresponding chalcone analogues (<bold>C1</bold>&#x0223c;<bold>C4</bold>). Especially, compound <bold>D6</bold> showed the potently inhibitory effect with an IC<sub>50</sub> value of 0.14&#x02009;&#x003bc;M (&#x0003e; 100-fold more potent than <bold>C3</bold>). This result suggests that dithiocarbamate moiety may play a synergistic role in determining activity.</p><table-wrap id="t0001" orientation="portrait" position="float"><label>Table 1.</label><caption><p><italic>In vitro</italic> inhibitory activities of compounds <bold>C1</bold>&#x0223c;<bold>C4</bold> and <bold>D1</bold>&#x0223c;<bold>D7</bold> to LSD1 and its homologies MAO-A and MAO-B <inline-graphic xlink:href="IENZ_A_1852556_ILG0001_B.jpg" content-type="black-white"/></p></caption><!--OASIS TABLE HERE--><table frame="hsides" rules="groups"><colgroup><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/></colgroup><thead><tr><th rowspan="2" align="left">Compound</th><th rowspan="2" align="center">R1</th><th rowspan="2" align="center">R2</th><th colspan="3" align="center">IC<sub>50</sub> (&#x003bc;M)<hr/></th></tr><tr><th align="center">LSD1</th><th align="center">MAO-A</th><th align="center">MAO-AB</th></tr></thead><tbody valign="top"><tr><td align="left"><bold>C1</bold></td><td align="center"><bold>H</bold></td><td align="center"><bold>-</bold></td><td align="center">&#x0003e;20</td><td align="char" char=".">&#x0003e;20</td><td align="char" char=".">&#x0003e;20</td></tr><tr><td align="left"><bold>C2</bold></td><td align="center"><bold>3-F</bold></td><td align="center"><bold>-</bold></td><td align="center">19.70&#x02009;&#x000b1;&#x02009;0.67</td><td align="char" char=".">&#x0003e;20</td><td align="char" char=".">&#x0003e;20</td></tr><tr><td align="left"><bold>C3</bold></td><td align="center"><bold>2-F</bold></td><td align="center"><bold>-</bold></td><td align="center">15.35&#x02009;&#x000b1;&#x02009;0.28</td><td align="char" char=".">&#x0003e;20</td><td align="char" char=".">&#x0003e;20</td></tr><tr><td align="left"><bold>C4</bold></td><td align="center"><bold>4-F</bold></td><td align="center"><bold>-</bold></td><td align="center">&#x0003e;20</td><td align="char" char=".">&#x0003e;20</td><td align="char" char=".">&#x0003e;20</td></tr><tr><td align="left"><bold>D1</bold></td><td align="center"><bold>4-F</bold></td><td align="center"><inline-graphic xlink:href="IENZ_A_1852556_ILG0002_B.gif" content-type="black-white"/></td><td align="center">11.26&#x02009;&#x000b1;&#x02009;0.13</td><td align="char" char=".">&#x0003e;20</td><td align="char" char=".">&#x0003e;20</td></tr><tr><td align="left"><bold>D2</bold></td><td align="center"><bold>H</bold></td><td align="center"><inline-graphic xlink:href="IENZ_A_1852556_ILG0003_B.gif" content-type="black-white"/></td><td align="center">9.35&#x02009;&#x000b1;&#x02009;0.14</td><td align="char" char=".">&#x0003e;20</td><td align="char" char=".">&#x0003e;20</td></tr><tr><td align="left"><bold>D3</bold></td><td align="center"><bold>H</bold></td><td align="center"><inline-graphic xlink:href="IENZ_A_1852556_ILG0004_B.gif" content-type="black-white"/></td><td align="center">13.90&#x02009;&#x000b1;&#x02009;0.18</td><td align="char" char=".">&#x0003e;20</td><td align="char" char=".">&#x0003e;20</td></tr><tr><td align="left"><bold>D4</bold></td><td align="center"><bold>3-F</bold></td><td align="center"><inline-graphic xlink:href="IENZ_A_1852556_ILG0005_B.gif" content-type="black-white"/></td><td align="center">6.03&#x02009;&#x000b1;&#x02009;0.17</td><td align="char" char=".">&#x0003e;20</td><td align="char" char=".">&#x0003e;20</td></tr><tr><td align="left"><bold>D5</bold></td><td align="center"><bold>3-F</bold></td><td align="center"><inline-graphic xlink:href="IENZ_A_1852556_ILG0006_B.gif" content-type="black-white"/></td><td align="center">2.29&#x02009;&#x000b1;&#x02009;0.35</td><td align="char" char=".">&#x0003e;20</td><td align="char" char=".">&#x0003e;20</td></tr><tr><td align="left"><bold>D6</bold></td><td align="center"><bold>2-F</bold></td><td align="center"><inline-graphic xlink:href="IENZ_A_1852556_ILG0007_B.gif" content-type="black-white"/></td><td align="center">0.14&#x02009;&#x000b1;&#x02009;0.01</td><td align="char" char=".">&#x0003e;20</td><td align="char" char=".">&#x0003e;20</td></tr><tr><td align="left"><bold>D7</bold></td><td align="center"><bold>2-F</bold></td><td align="center"><inline-graphic xlink:href="IENZ_A_1852556_ILG0008_B.gif" content-type="black-white"/></td><td align="center">3.27&#x02009;&#x000b1;&#x02009;0.13</td><td align="char" char=".">&#x0003e;20</td><td align="char" char=".">&#x0003e;20</td></tr><tr><td align="left"><bold>Dithiocarbamate 26</bold><sup>a</sup></td><td align="center"><bold>-</bold></td><td align="center"><bold>-</bold></td><td align="center">2.68&#x02009;&#x000b1;&#x02009;0.12</td><td align="char" char=".">&#x0003e;20</td><td align="char" char=".">&#x0003e;20</td></tr><tr><td align="left"><bold>Chalcone 4</bold><sup>a</sup></td><td align="center"><bold>-</bold></td><td align="center"><bold>-</bold></td><td align="center">&#x0003e;20</td><td align="char" char=".">&#x0003e;20</td><td align="char" char=".">&#x0003e;20</td></tr></tbody></table><table-wrap-foot><fn id="TF1"><p><sup>a</sup><bold>Dithiocarbamate 26</bold> and <bold>Chalcone 4</bold> were used as control.</p></fn></table-wrap-foot></table-wrap><p>As LSD1 belongs to the monoamine oxidase (MAO) family, the inhibitory effects of compounds <bold>C1</bold>&#x0223c;<bold>C4</bold> and <bold>D1</bold>&#x0223c;<bold>D7</bold> to its homologies MAO-A and MAO-B were also examined using commercially available kits<xref rid="CIT0028" ref-type="bibr"><sup>28</sup></xref><sup>,</sup><xref rid="CIT0029" ref-type="bibr"><sup>29</sup></xref>. From the results of <xref rid="t0001" ref-type="table">Table 1</xref>, all synthesised compounds <bold>C1</bold>&#x0223c;<bold>C4</bold> and <bold>D1</bold>&#x0223c;<bold>D7</bold> had no significant effects on MAO-A and MAO-B. These findings indicated the high selectivity of chalcone-dithiocarbamate inhibitors <bold>D1</bold>&#x0223c;<bold>D7</bold> on LSD1 <italic>in&#x000a0;vitro</italic>. In addition, we found that the substitution on the phenyl ring was important for the activity showing an over 6-fold activity loss, when the fluorine atom was replaced with the hydrogen atom (compounds <bold>D3</bold> vs. <bold>D5</bold>). Replacement of the ethyl group of compound <bold>D5</bold> with a methyl group (<bold>D4</bold>) led to a loss of the activity. However, changing the benzyl group (compound <bold>D7</bold>) to a tert-butoxycarbonyl group (compound <bold>D6</bold>) led to a significant improvement of the activity against LSD1. All these results indicated that the substituent group at piperazine ring may play an important role for their inhibitory activity. The detailed illustration for preliminary structure activity relationship (SAR) of target derivatives was showed in <xref ref-type="scheme" rid="s0002">Scheme 2</xref>.</p><fig id="s0002" orientation="portrait" position="float"><label>Scheme 2.</label><caption><p>Summary of preliminary SAR.</p></caption><graphic content-type="color" xlink:href="IENZ_A_1852556_SCH0002_C"/></fig></sec><sec id="S0003-S2003" disp-level="2"><title>Antiproliferative effects of chalcone D6 against different cancer cell lines</title><p>Based on the screening activity results of all synthetic derivatives, the most potent chalcone <bold>D6</bold> was prioritised to perform further experiments for evaluating its antiproliferative potential. In addition, Hela (cervical cancer cells), 22RV1 (prostate cancer cells), Caco-2 (colon cancer cells), BEL-7402 (liver cancer cells), MOLT-4 (leukaemia cells), OVCAR-3 (ovarian cancer cells), HCT-8 (cecal adenocarcinoma cells) and IMR-32 (neuroblastoma cells) were treated with compound <bold>D6</bold> at different concentrations (control, 4&#x02009;&#x003bc;M, 8&#x02009;&#x003bc;M, and 16&#x02009;&#x003bc;M). As shown in <xref ref-type="fig" rid="F0004">Figure 4</xref>, chalcone <bold>D6</bold> displayed the potential antiproliferative effects against 22RV1, Caco-2, MOLT-4 and IMR-32 cells. Among them, chalcone <bold>D6</bold> showed the most potent antiproliferation efficiency around 80% for 48&#x02009;h at 4&#x02009;&#x003bc;M against leukaemia MOLT-4 cells. These results indicated that chalcone <bold>D6</bold> might be a broad-spectrum antitumor agent.</p><fig id="F0004" orientation="portrait" position="float"><label>Figure 4.</label><caption><p>Cell viability of <bold>D6</bold> against different cancer cell lines for 48&#x02009;h and 72&#x02009;h. *<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05, **<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.01, ***<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001, and ****<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.0001 were considered statistically significant compared with the control.</p></caption><graphic content-type="color" xlink:href="IENZ_A_1852556_F0004_C"/></fig></sec><sec id="S0003-S2004" disp-level="2"><title>Chalcone D6 exhibited the potently antitumor activity <italic>in&#x000a0;vitro</italic> against leukaemia cells</title><p>Based on the antiproliferative results, concentrations of 0.5&#x02009;&#x003bc;M, 1&#x02009;&#x003bc;M, 2&#x02009;&#x003bc;M, and 4&#x02009;&#x003bc;M were chosen to investigate the proliferation effects of chalcone <bold>D6</bold> on the cell viability of leukaemia cells (HAL-01, KE-37, P30-OHK, SUP-B15, MOLT-4 and LC4-1). We added the 5-Fluorouracil as a positive control to do the cytotoxicity assays in these leukaemia cells. The IC<sub>50</sub> values of 5-Fluorouracil against HAL-01, KE-37, P30-OHK, SUP-B15, MOLT-4 and LC4-1 cells were 5.10&#x02009;&#x003bc;M, 4.02&#x02009;&#x003bc;M, 4.17&#x02009;&#x003bc;M, 2.10&#x02009;&#x003bc;M, 2.89&#x02009;&#x003bc;M and 10.2&#x02009;&#x003bc;M, respectively. From the results of <xref ref-type="fig" rid="F0005">Figure 5</xref>, chalcone <bold>D6</bold> inhibited cell proliferation with IC<sub>50</sub> values of 1.10&#x02009;&#x003bc;M, 3.64&#x02009;&#x003bc;M, 3.85&#x02009;&#x003bc;M, 1.87&#x02009;&#x003bc;M, 0.87&#x02009;&#x003bc;M and 2.73&#x02009;&#x003bc;M against HAL-01, KE-37, P30-OHK, SUP-B15, MOLT-4 and LC4-1 leukaemia cells. These findings supported that chalcone <bold>D6</bold> potently inhibited cell proliferation against leukaemia cells in a concentration dependent manner.</p><fig id="F0005" orientation="portrait" position="float"><label>Figure 5.</label><caption><p>Antitumor activity <italic>in&#x000a0;vitro</italic> of <bold>D6</bold> against leukaemia cells. *<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05, **<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.01, ***<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001, and ****<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.0001 were considered statistically significant compared with the control.</p></caption><graphic content-type="color" xlink:href="IENZ_A_1852556_F0005_C"/></fig></sec><sec id="S0003-S2005" disp-level="2"><title>Chalcone D6 selectively inhibited LSD1 in a time dependent and reversible manner</title><p>LSD1 belonged to the FAD dependent monoamine oxidases family including MAO-A and MAO-B, and shared the similar enzymatic mechanism of MAO-A/B<xref rid="CIT0030" ref-type="bibr"><sup>30</sup></xref>. In addition, chalcone-based analogues represented a privileged scaffold for developing inhibitors of cyclin-dependent kinases<xref rid="CIT0031" ref-type="bibr"><sup>31</sup></xref>. Thus, the selectivity of chalcone <bold>D6</bold> against homologous proteins MAO-A/B and CDK1/2 was explored in this work. As shown in <xref ref-type="fig" rid="F0006">Figure 6(A)</xref>, chalcone <bold>D6</bold> at 400&#x02009;nM weakly inhibited MAO-A, MAO-B, CDK1 and CDK2 with the rates of only 16.3%, 17.7%, 16.3% and 19.0%, respectively, while it showed about 99.3% of inhibition against LSD1. These findings indicated the high selectivity of chalcone <bold>D6</bold> on LSD1 <italic>in&#x000a0;vitro</italic>. Then, time-dependent experiments were also performed and results showed that chalcone <bold>D6</bold> inhibited LSD1 in a time dependent manner (<xref ref-type="fig" rid="F0006">Figure 6(B)</xref>). Importantly, the dialysis experiment (<xref ref-type="fig" rid="F0006">Figure 6(C)</xref>) and dilution assay (<xref ref-type="fig" rid="F0006">Figure 6(D)</xref>) indicating that chalcone <bold>D6</bold> was a reversible LSD1 inhibitor. To further confirm the potential binding manner of chalcone <bold>D6</bold> against LSD1 recombinant, the centrifuge experiment was also carried out. With the aid of 10&#x02009;kDa ultracentrifuge filter, reversible compound was supposed to be removed from LSD1 by centrifuge. So, chalcone <bold>D6</bold> was characterised as a reversible LSD1 inhibitor as split of chalcone <bold>D6</bold> by ultracentrifuge may rescue the activity of LSD1 (<xref ref-type="fig" rid="F0006">Figure 6(E)</xref>). All these results showed that chalcone <bold>D6</bold> could selectively inhibit LSD1 in a time dependent and reversible manner.</p><fig id="F0006" orientation="portrait" position="float"><label>Figure 6.</label><caption><p>(A) <italic>In vitro</italic> enzyme inhibition of <bold>D6</bold> (200&#x02009;nM, 300&#x02009;nM and 400&#x02009;nM) against LSD1, MAO-A/B and CDK1/2. (B) Inhibitory Rates of <bold>D6</bold> against LSD1. (C, D, E) The dialysis experiments, dilution assay and ultrafiltration experiments of <bold>D6</bold>. GSK-LSD1 was used as a positive control.</p></caption><graphic content-type="color" xlink:href="IENZ_A_1852556_F0006_C"/></fig></sec><sec id="S0003-S2006" disp-level="2"><title>Antiproliferative effects of chalcone D6 against MOLT-4 LSD1 knockdown cells</title><p>LSD1 was aberrantly over-expressed in leukaemia cells, and associated with tumorigenesis<xref rid="CIT0032" ref-type="bibr"><sup>32</sup></xref>. In view of the inhibitory potency against LSD1, chalcone <bold>D6</bold> was chosen for further antiproliferative studies. In this work, we used the LSD1 knock-down MOLT-4 cells (MOLT-4&#x00026;shLSD1) and control cells (MOLT-4&#x00026;shControl) to investigate its antiproliferative activity. Firstly, the gene expression of LSD1 in MOLT-4&#x00026;shLSD1 cells and MOLT-4&#x00026;shControl cells was detected by quantitative real-time PCR, the results were shown in <xref ref-type="fig" rid="F0007">Figure 7(A)</xref>. With these two cell lines in hand, we nextly used the MTT assay to examine the antiproliferative effects of chalcone <bold>D6</bold> against MOLT-4&#x00026;shLSD1 cells and MOLT-4&#x00026;shControl cells. As shown in <xref ref-type="fig" rid="F0007">Figure 7(B)</xref>, chalcone <bold>D6</bold> significantly suppressed the proliferation of MOLT-4&#x00026;shControl cells in a concentration dependent manner with the IC<sub>50</sub> value of 0.89&#x02009;&#x003bc;M. In contrast, <bold>D6</bold> inhibited MOLT-4&#x00026;shLSD1 cells with the IC<sub>50</sub> value of 7.83&#x02009;&#x003bc;M, about 8&#x02009;&#x0223c;&#x02009;9-fold less potent against MOLT-4&#x00026;shControl cells. The activity discrepancy observed indicated that the antiproliferative effects of chalcone <bold>D6</bold> against MOLT-4 cells were dependent on LSD1 inhibition, and also suggested that chalcone <bold>D6</bold> was cellularly active against LSD1, excluding off-target effects.</p><fig id="F0007" orientation="portrait" position="float"><label>Figure 7.</label><caption><p>(A) The gene expression of LSD1 in MOLT-4&#x00026;shLSD1 cells and MOLT-4&#x00026;shControl cells. (B) Antiproliferative effects of <bold>D6</bold> against MOLT-4&#x00026;shLSD1 cells and MOLT-4&#x00026;shControl cells. ****<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.0001 was considered statistically significant compared with the control.</p></caption><graphic content-type="color" xlink:href="IENZ_A_1852556_F0007_C"/></fig></sec><sec id="S0003-S2007" disp-level="2"><title>Chalcone D6 regulated the expression of LSD1 substrates H3K9me1/2</title><p>To further determine the inhibitory effects of chalcone <bold>D6</bold> against LSD1 in MOLT-4 cells, amount of two reported LSD1 substrates H3K9me1 and H3K9me2 were analysed by western blotting experiments. As shown in <xref ref-type="fig" rid="F0008">Figure 8</xref>, the amount of H3K9me1 and H3K9me2 showed a concentration dependent accumulation in the presence of chalcone <bold>D6</bold>. In addition, the treatment of <bold>D6</bold> in MOLT-4 cells did not affect the expression level of LSD1. Collectively, these results suggested that chalcone <bold>D6</bold> is a cellular active LSD1 inhibitor in leukaemia MOLT-4 cells.</p><fig id="F0008" orientation="portrait" position="float"><label>Figure 8.</label><caption><p>The amount of H3K9me1 and H3K9me2 in MOLT-4 cells treated by chalcone <bold>D6</bold>. **<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.01, ***<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001 and ****<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.0001 were considered statistically significant compared with the control.</p></caption><graphic content-type="black-white" xlink:href="IENZ_A_1852556_F0008_B"/></fig></sec><sec id="S0003-S2008" disp-level="2"><title>Molecular docking of chalcone D6</title><p>Based on the above experiments, chalcone <bold>D6</bold> has been identified as a novel LSD1 inhibitor. In the current work, molecular docking methodologies were also used to explore any molecular interaction exist between chalcone <bold>D6</bold> and residues lies in the active site cativity of LSD1. We have used Autodock as an automated tool to perform docking and selected PDB code 5l3e (Resolution: 2.80&#x02009;&#x000c5;). As shown in <xref ref-type="fig" rid="F0009">Figure 9</xref>, chalcone <bold>D6</bold> formed three hydrogen bonds with residues His532, Asn535 and Asp556, respectively. In addition, chalcone <bold>D6</bold> formed hydrophobic effects with residues Leu386, Phe382 and Phe538. These results explained that chalcone scaffold was a promising unit for targeting LSD1. Based on the reported reference [<xref rid="CIT0033" ref-type="bibr">33</xref>], <bold>E11</bold> as a reference compound was docked using the same protocol and compared with chalcone <bold>D6</bold>. In the <xref ref-type="fig" rid="F0009">Figure 9</xref>, the reference compound <bold>E11</bold> (yellow structure) was docked into a similar pocket as chalcone <bold>D6</bold> (magenta structure).</p><fig id="F0009" orientation="portrait" position="float"><label>Figure 9.</label><caption><p>Molecular docking studies of chalcone <bold>D6</bold>. (A) The complex formed between LSD1 and compound <bold>D6</bold>. (B) A similar pocket between the reference compound <bold>E11</bold> (yellow structure) and <bold>D6</bold> (magenta structure).</p></caption><graphic content-type="color" xlink:href="IENZ_A_1852556_F0009_C"/></fig></sec><sec id="S0003-S2009" disp-level="2"><title>Xenograft study of chalcone D6</title><p>Since the potently antiproliferative activity of chalcone <bold>D6</bold> against MOLT-4 cells, we also evaluated the anticancer effects of chalcone <bold>D6</bold> on xenograft models bearing MOLT-4 cells. After the treatment of chalcone <bold>D6</bold> (60&#x02009;mg/kg and 100&#x02009;mg/kg), the body weight of mice, the tumour weight and the tumour volume were measured and recorded. As shown in <xref ref-type="fig" rid="F0010">Figure 10</xref>, chalcone <bold>D6</bold> inhibited tumour growth remarkably, while the body weight was almost unchanged, suggesting the antitumor efficacy and low global toxicity.</p><fig id="F0010" orientation="portrait" position="float"><label>Figure 10.</label><caption><p><italic>In vivo</italic> anticancer effects of chalcone <bold>D6</bold>. (A) Tumour volume. (B) Tumour weight. <bold>C</bold> Weight of mice. **<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.01 and ***<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001 were considered statistically significant compared with the control.</p></caption><graphic content-type="black-white" xlink:href="IENZ_A_1852556_F0010_B"/></fig></sec></sec><sec sec-type="conclusions" id="S0004" disp-level="1"><title>Conclusion</title><p>A series of chalcone derivatives were designed, synthesised and evaluated for LSD1 inhibitory activity. All chalcone-dithiocarbamate hybrids <bold>D1</bold>&#x0223c;<bold>D7</bold> exhibited potentially inhibitory activity against LSD1. Especially, chalcone <bold>D6</bold> showed the best LSD1 inhibitory activity with an IC<sub>50</sub> value of 0.14&#x02009;&#x003bc;M. In addition, <bold>D6</bold> inhibited cell proliferation with IC<sub>50</sub> values of 1.10&#x02009;&#x003bc;M, 3.64&#x02009;&#x003bc;M, 3.85&#x02009;&#x003bc;M, 1.87&#x02009;&#x003bc;M, 0.87&#x02009;&#x003bc;M and 2.73&#x02009;&#x003bc;M against HAL-01, KE-37, P30-OHK, SUP-B15, MOLT-4 and LC4-1 leukaemia cells. Further investigations demonstrated that compound <bold>D6</bold> selectively inhibited LSD1 in a time dependent and reversible manner. It also up-regulated the expression levels of H3K9me1 and H3K9me2 against MOLT-4 cells. Importantly, chalcone <bold>D6</bold> inhibited <italic>in&#x000a0;vivo</italic> tumour growth in a xenograft model without apparent toxicity. Taken together, chalcone <bold>D6</bold> could be a lead candidate for its further development in the treatment of leukaemia.</p></sec><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="SM5126"><caption><title>Supplemental Material</title></caption><media xlink:href="IENZ_A_1852556_SM5126.pdf"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ack><title>Acknowledgements</title><p>The authors thank the supports from Shengjing Hospital of China Medical University.</p></ack><sec id="S0005" disp-level="1" sec-type="COI-statement"><title>Disclosure statement</title><p>No potential conflict of interest was reported by the author(s).</p></sec><notes><sec sec-type="correction-statement"><title>Correction Statement</title><p>This article has been republished with minor changes. These changes do not impact the academic content of the article.</p></sec></notes><ref-list><title>References</title><ref id="CIT0001"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sugino</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Kawahara</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Tatsumi</surname><given-names>G</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>A novel LSD1 inhibitor NCD38 ameliorates MDS-related leukemia with complex karyotype by attenuating leukemia programs via activating super-enhancers</article-title>. <source>Leukemia</source>
<year>2017</year>;<volume>31</volume>:<fpage>2303</fpage>&#x02013;<lpage>14</lpage>.<pub-id pub-id-type="pmid">28210006</pub-id></mixed-citation></ref><ref id="CIT0002"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tatsumi</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Kawahara</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Yamamoto</surname><given-names>R</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>LSD1-mediated repression of GFI1 super-enhancer plays an essential role in erythroleukemia</article-title>. <source>Leukemia</source>
<year>2020</year>;<volume>34</volume>:<fpage>746</fpage>&#x02013;<lpage>58</lpage>.<pub-id pub-id-type="pmid">31676828</pub-id></mixed-citation></ref><ref id="CIT0003"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yamamoto</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Kawahara</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Ito</surname><given-names>S</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Selective dissociation between LSD1 and GFI1B by a LSD1 inhibitor NCD38 induces the activation of ERG super-enhancer in erythroleukemia cells</article-title>. <source>Oncotarget</source>
<year>2018</year>;<volume>9</volume>:<fpage>21007</fpage>&#x02013;<lpage>21</lpage>.<pub-id pub-id-type="pmid">29765516</pub-id></mixed-citation></ref><ref id="CIT0004"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Feng</surname><given-names>Z</given-names></name>, <name name-style="western"><surname>Yao</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Zhou</surname><given-names>C</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Pharmacological inhibition of LSD1 for the treatment of MLL-rearranged leukemia</article-title>. <source>J Hematol Oncol</source>
<year>2016</year>;<volume>9</volume>:<fpage>24</fpage>.<pub-id pub-id-type="pmid">26970896</pub-id></mixed-citation></ref><ref id="CIT0005"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Przespolewski</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>ES.</given-names></name></person-group>
<article-title>Inhibitors of LSD1 as a potential therapy for acute myeloid leukemia</article-title>. <source>Expert Opin Investig Drugs</source>
<year>2016</year>;<volume>25</volume>:<fpage>771</fpage>&#x02013;<lpage>80</lpage>.</mixed-citation></ref><ref id="CIT0006"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mould</surname><given-names>DP</given-names></name>, <name name-style="western"><surname>McGonagle</surname><given-names>AE</given-names></name>, <name name-style="western"><surname>Wiseman</surname><given-names>DH</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Reversible inhibitors of LSD1 as therapeutic agents in acute myeloid leukemia: clinical significance and progress to date</article-title>. <source>Med Res Rev</source>
<year>2015</year>;<volume>35</volume>:<fpage>586</fpage>&#x02013;<lpage>618</lpage>.<pub-id pub-id-type="pmid">25418875</pub-id></mixed-citation></ref><ref id="CIT0007"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zheng</surname><given-names>YC</given-names></name>, <name name-style="western"><surname>Duan</surname><given-names>YC</given-names></name>, <name name-style="western"><surname>Ma</surname><given-names>JL</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Triazole-dithiocarbamate based selective lysine specific demethylase 1 (LSD1) inactivators inhibit gastric cancer cell growth, invasion, and migration</article-title>. <source>J Med Chem</source>
<year>2013</year>;<volume>56</volume>:<fpage>8543</fpage>&#x02013;<lpage>60</lpage>.<pub-id pub-id-type="pmid">24131029</pub-id></mixed-citation></ref><ref id="CIT0008"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sharma</surname><given-names>SK</given-names></name>, <name name-style="western"><surname>Wu</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Steinbergs</surname><given-names>N</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>(Bis)urea and (bis)thiourea inhibitors of lysine-specific demethylase 1 as epigenetic modulators</article-title>. <source>J Med Chem</source>
<year>2010</year>;<volume>53</volume>:<fpage>5197</fpage>&#x02013;<lpage>212</lpage>.<pub-id pub-id-type="pmid">20568780</pub-id></mixed-citation></ref><ref id="CIT0009"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ahmadi</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Mardinia</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Azimi</surname><given-names>N</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Prediction of chalcone derivative cytotoxicity activity against MCF-7 human breast cancer cell by Monte Carlo method</article-title>. <source>J Mol Struct</source>
<year>2019</year>;<volume>1181</volume>:<fpage>305</fpage>&#x02013;<lpage>11</lpage>.</mixed-citation></ref><ref id="CIT0010"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Riaz</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Iqbal</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Ullah</surname><given-names>R</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Synthesis and evaluation of novel &#x003b1;-substituted chalcones with potent anti-cancer activities and ability to overcome multidrug resistance</article-title>. <source>Bioorg Chem</source>
<year>2019</year>;<volume>87</volume>:<fpage>123</fpage>&#x02013;<lpage>35</lpage>.<pub-id pub-id-type="pmid">30884306</pub-id></mixed-citation></ref><ref id="CIT0011"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhuang</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Sheng</surname><given-names>C</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Chalcone: a privileged structure in medicinal chemistry</article-title>. <source>Chem Rev</source>
<year>2017</year>;<volume>117</volume>:<fpage>7762</fpage>&#x02013;<lpage>810</lpage>.<pub-id pub-id-type="pmid">28488435</pub-id></mixed-citation></ref><ref id="CIT0012"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sangpheak</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Mueller</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Darai</surname><given-names>N</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Computational screening of chalcones acting against topoisomerase II&#x003b1; and their cytotoxicity towards cancer cell lines</article-title>. <source>J Enzyme Inhib Med Chem</source>
<year>2019</year>;<volume>34</volume>:<fpage>134</fpage>&#x02013;<lpage>43</lpage>.<pub-id pub-id-type="pmid">30394113</pub-id></mixed-citation></ref><ref id="CIT0013"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lamie</surname><given-names>PF</given-names></name>, <name name-style="western"><surname>Philoppes</surname><given-names>J.</given-names></name></person-group>
<article-title>N 2-Thiopyrimidine/chalcone hybrids: design, synthesis, ADMET prediction, and anticancer evaluation as STAT3/STAT5a inhibitors</article-title>. <source>J Enzyme Inhib Med Chem</source>
<year>2020</year>;<volume>35</volume>:<fpage>864</fpage>&#x02013;<lpage>79</lpage>.<pub-id pub-id-type="pmid">32208772</pub-id></mixed-citation></ref><ref id="CIT0014"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>CP</given-names></name>, <name name-style="western"><surname>Lusvarghi</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Hsiao</surname><given-names>SH</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Licochalcone A selectively resensitizes ABCG2-overexpressing multidrug-resistant cancer cells to chemotherapeutic drugs</article-title>. <source>J Nat Prod</source>
<year>2020</year>;<volume>83</volume>:<fpage>1461</fpage>&#x02013;<lpage>72</lpage>.<pub-id pub-id-type="pmid">32347726</pub-id></mixed-citation></ref><ref id="CIT0015"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Quaglio</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Zhdanovskaya</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Tobajas</surname><given-names>G</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Chalcones and chalcone-mimetic derivatives as notch inhibitors in a model of T-cell acute lymphoblastic leukemia</article-title>. <source>ACS Med Chem Lett</source>
<year>2019</year>;<volume>10</volume>:<fpage>639</fpage>&#x02013;<lpage>43</lpage>.<pub-id pub-id-type="pmid">30996810</pub-id></mixed-citation></ref><ref id="CIT0016"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Gong</surname><given-names>Z</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Synthesis, biological evaluation, and molecular modelling of new naphthalene-chalcone derivatives as potential anticancer agents on MCF-7 breast cancer cells by targeting tubulin colchicine binding site</article-title>. <source>J Enzyme Inhib Med Chem</source>
<year>2020</year>;<volume>35</volume>:<fpage>139</fpage>&#x02013;<lpage>44</lpage>.<pub-id pub-id-type="pmid">31724435</pub-id></mixed-citation></ref><ref id="CIT0017"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>dos Santos</surname><given-names>MB</given-names></name>, <name name-style="western"><surname>Bertholin Anselmo</surname><given-names>D</given-names></name>, <name name-style="western"><surname>de Oliveira</surname><given-names>JG</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Antiproliferative activity and p53 upregulation effects of chalcones on human breast cancer cells</article-title>. <source>J Enzyme Inhib Med Chem</source>
<year>2019</year>;<volume>34</volume>:<fpage>1093</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">31117836</pub-id></mixed-citation></ref><ref id="CIT0018"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Viegas-Junior</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Danuello</surname><given-names>A</given-names></name>, <name name-style="western"><surname>da</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Bolzani</surname><given-names>V</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Molecular hybridization: a useful tool in the design of new drug prototypes</article-title>. <source>Curr Med Chem</source>
<year>2007</year>;<volume>14</volume>:<fpage>1829</fpage>&#x02013;<lpage>52</lpage>.<pub-id pub-id-type="pmid">17627520</pub-id></mixed-citation></ref><ref id="CIT0019"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gan</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Hu</surname><given-names>D</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Design, synthesis, and antiviral activity of novel chalcone derivatives containing a purine moiety</article-title>. <source>Chinese J Chem</source>
<year>2017</year>;<volume>35</volume>:<fpage>665</fpage>&#x02013;<lpage>72</lpage>.</mixed-citation></ref><ref id="CIT0020"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Singh</surname><given-names>MM</given-names></name>, <name name-style="western"><surname>Manton</surname><given-names>CA</given-names></name>, <name name-style="western"><surname>Bhat</surname><given-names>KP</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Inhibition of LSD1 sensitizes glioblastoma cells to histone deacetylase inhibitors</article-title>. <source>Neuro Oncol</source>
<year>2011</year>;<volume>13</volume>:<fpage>894</fpage>&#x02013;<lpage>903</lpage>.<pub-id pub-id-type="pmid">21653597</pub-id></mixed-citation></ref><ref id="CIT0021"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hayami</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Kelly</surname><given-names>JD</given-names></name>, <name name-style="western"><surname>Cho</surname><given-names>HS</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Overexpression of LSD1 contributes to human carcinogenesis through chromatin regulation in various cancers</article-title>. <source>Int J Cancer</source>
<year>2011</year>;<volume>128</volume>:<fpage>574</fpage>&#x02013;<lpage>86</lpage>.<pub-id pub-id-type="pmid">20333681</pub-id></mixed-citation></ref><ref id="CIT0022"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hoshino</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Akutsu</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Murakami</surname><given-names>K</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Histone demethylase LSD1 inhibitors prevent cell growth by regulating gene expression in esophageal squamous cell carcinoma cells</article-title>. <source>Ann Surg Oncol</source>
<year>2016</year>;<volume>23</volume>:<fpage>312</fpage>&#x02013;<lpage>20</lpage>.<pub-id pub-id-type="pmid">25791791</pub-id></mixed-citation></ref><ref id="CIT0023"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gehling</surname><given-names>VS</given-names></name>, <name name-style="western"><surname>McGrath</surname><given-names>JP</given-names></name>, <name name-style="western"><surname>Duplessis</surname><given-names>M</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Design and synthesis of styrenylcyclopropylamine LSD1 inhibitors</article-title>. <source>ACS Med Chem Lett</source>
<year>2020</year>;<volume>11</volume>:<fpage>1213</fpage>&#x02013;<lpage>20</lpage>.<pub-id pub-id-type="pmid">32551003</pub-id></mixed-citation></ref><ref id="CIT0024"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fioravanti</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Romanelli</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Mautone</surname><given-names>N</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Tranylcypromine-based LSD1 inhibitors: structure-activity relationships, antiproliferative effects in leukemia, and gene target modulation</article-title>. <source>ChemMedChem</source>
<year>2020</year>;<volume>15</volume>:<fpage>643</fpage>&#x02013;<lpage>58</lpage>.<pub-id pub-id-type="pmid">32003940</pub-id></mixed-citation></ref><ref id="CIT0025"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Yang</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Song</surname><given-names>Q</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Pyridoxine-resveratrol hybrids as novel inhibitors of MAO-B with antioxidant and neuroprotective activities for the treatment of Parkinson&#x02019;s disease</article-title>. <source>Bioorg Chem</source>
<year>2020</year>;<volume>97</volume>:<fpage>103707</fpage><pub-id pub-id-type="pmid">32146176</pub-id></mixed-citation></ref><ref id="CIT0026"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wilson</surname><given-names>SC</given-names></name>, <name name-style="western"><surname>Atrash</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Barlow</surname><given-names>C</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Design, synthesis and biological evaluation of 6-pyridylmethylaminopurines as CDK inhibitors</article-title>. <source>Bioorg Med Chem</source>
<year>2011</year>;<volume>19</volume>:<fpage>6949</fpage>&#x02013;<lpage>65</lpage>.<pub-id pub-id-type="pmid">21982796</pub-id></mixed-citation></ref><ref id="CIT0027"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Valente</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Rodriguez</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Mercurio</surname><given-names>C</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Pure enantiomers of benzoylamino-tranylcypromine: LSD1 inhibition, gene modulation in human leukemia cells and effects on clonogenic potential of murine promyelocytic blasts</article-title>. <source>Eur J Med Chem</source>
<year>2015</year>;<volume>94</volume>:<fpage>163</fpage>&#x02013;<lpage>74</lpage>.<pub-id pub-id-type="pmid">25768700</pub-id></mixed-citation></ref><ref id="CIT0028"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Su</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>Y</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Tranylcypromine and 6-trifluoroethyl thienopyrimidine hybrid as LSD1 inhibitor</article-title>. <source>Bioorg Med Chem Lett</source>
<year>2019</year>;<volume>29</volume>:<fpage>844</fpage>&#x02013;<lpage>7</lpage>.<pub-id pub-id-type="pmid">30713023</pub-id></mixed-citation></ref><ref id="CIT0029"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schulz-Fincke</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Hau</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Barth</surname><given-names>J</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Structure-activity studies on N-Substituted tranylcypromine derivatives lead to selective inhibitors of lysine specific demethylase 1 (LSD1) and potent inducers of leukemic cell differentiation</article-title>. <source>Eur J Med Chem</source>
<year>2018</year>;<volume>144</volume>:<fpage>52</fpage>&#x02013;<lpage>67</lpage>.<pub-id pub-id-type="pmid">29247860</pub-id></mixed-citation></ref><ref id="CIT0030"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Holshouser</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Dunworth</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Murray-Stewart</surname><given-names>T</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Dual inhibitors of LSD1 and spermine oxidase</article-title>. <source>MedChemComm</source>
<year>2019</year>;<volume>10</volume>:<fpage>778</fpage>&#x02013;<lpage>90</lpage>.<pub-id pub-id-type="pmid">31191868</pub-id></mixed-citation></ref><ref id="CIT0031"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Geyer</surname><given-names>JA</given-names></name>, <name name-style="western"><surname>Keenan</surname><given-names>SM</given-names></name>, <name name-style="western"><surname>Woodard</surname><given-names>CL</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Selective inhibition of Pfmrk, a Plasmodium falciparum CDK, by antimalarial 1,3-diaryl-2-propenones</article-title>. <source>Bioorg Med Chem Lett</source>
<year>2009</year>;<volume>19</volume>:<fpage>1982</fpage>&#x02013;<lpage>5</lpage>.<pub-id pub-id-type="pmid">19250824</pub-id></mixed-citation></ref><ref id="CIT0032"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zou</surname><given-names>ZK</given-names></name>, <name name-style="western"><surname>Huang</surname><given-names>YQ</given-names></name>, <name name-style="western"><surname>Zou</surname><given-names>Y</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Silencing of LSD1 gene modulates histone methylation and acetylation and induces the apoptosis of JeKo-1 and MOLT-4 cells</article-title>. <source>Int J Mol Med</source>
<year>2017</year>;<volume>40</volume>:<fpage>319</fpage>&#x02013;<lpage>28</lpage>.<pub-id pub-id-type="pmid">28627608</pub-id></mixed-citation></ref><ref id="CIT0033"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Speranzini</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Rotili</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Ciossani</surname><given-names>G</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Polymyxins and quinazolines are LSD1/KDM1A inhibitors with unusual structural features</article-title>. <source>Sci Adv</source>
<year>2016</year>;<volume>2</volume>:<fpage>e1601017</fpage>.<pub-id pub-id-type="pmid">27626075</pub-id></mixed-citation></ref></ref-list></back></article>